NEU

2.59%

$13.56 neuren pharmaceuticals limited

FDA Grants Orphan Drug Designation, page-13

First 13 Last

Share
Profile

Follow
cuppa

9,520 Posts.

336

14/02/15

18:48

Post #: 14756105
Share

Originally posted by Megagene79 ↑

Overnight my US investor contacts informed me that the FDA has granted orphan drug designation to Neuron for its Rett Syndrome drug. This is great news as it is just the 1st part in the FDA decision making process with a decision on breakthrough designation to come next. We should get confirmation from NEU on Monday of this and this is very bullish and should see the uptrend continue. This granting of orphan drug status will give Neuron and additional 7 years exclusivity on the drug in turn basically extending the patent life an additional 7 years. Importantly this now allows the FDA to priority review Neuron's drug for Rett syndrome which is very bullish for receiving breakthrough designation. Orphan drug designation bodes very well for the next step in breakthrough designation which will be very very bullish for NEU when that hurdle is next jumped.

Recently the FDA has been inundated with lobbying pressure from patient groups for the approval of brain drugs with these groups not wanting to wait for the full approval process. For this reason breakthrough designation has now become a key in the next boom of breakthrough designation brain drugs. Also recently on the 27th of jan the US congress met to pass the Cure Act that further strengthens the FDA's ability to approve neuroscience and CNS (Central Nervous System) treatments after extensive pressure from patient groups.

It is not just patient lobbying but advancements in genetics and clinical science that will lead to a flood of new treatments for Autism, Depression, Alzheimer's and even Schizophrenia. Neuron is the leader in this field on the ASX and i would expect NEU to 1 day be the next billion $ ASX bio. The last pop into the teens was the last sale i will do now for NEU and wait for further developments now as we surge towards breakthrough designation and a move towards i believe a 500 mill market cap. I have also got in on the ground floor in Actinogen (ACW) as the brain drugs boom is very much on the way and with a market cap there of only 31 mill the upside is huge in just their Alzheimer's Dementia drug. Brain diseases are a major burden on sufferers and society as a whole and i believe 2 ASX companies will set the world alight as they develop their drugs to fight these diseases. Bring on Monday.

Expand

MEG,somehow as I was reading your post,I knew you would take an opportunity to plug ACW.That's the second time now.Your a crafty fellow arent you.

NEU Price at posting: 17.0¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

As Nvidia cools, we're looking to Aussie AI

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

CBA breaks trading record on strong day for Aussie financials

There are more pages in this discussion • 42 more messages in this thread...

First 13 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $13.56		Change -0.360(2.59%)		Mkt cap ! $1.733B

Open	High	Low	Value	Volume
$13.94	$13.96	$13.50	$6.421M	470.4K

Buyers (Bids)

No.	Vol.	Price($)
2	1643	$13.54

Sellers (Offers)

Price($)	Vol.	No.
$13.61	3100	1

View Market Depth

No.	Vol.	Price($)
1	3723	13.510
5	2576	13.500
1	1000	13.450
1	223	13.420
3	299	13.390

Price($)	Vol.	No.
13.900	242	1
13.920	650	1
13.960	47	1
14.000	1020	2
14.120	493	1

Last trade - 16.10pm 06/09/2024 (20 minute delay)

NEU (ASX) Chart

FDA Grants Orphan Drug Designation, page-13

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

As Nvidia cools, we're looking to Aussie AI

Shekel Brainweigh investor presentation webinar – the future of retail automation

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

CBA breaks trading record on strong day for Aussie financials

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

FDA Grants Orphan Drug Designation, page-13

Top Stories

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

As Nvidia cools, we're looking to Aussie AI

Shekel Brainweigh investor presentation webinar – the future of retail automation

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

CBA breaks trading record on strong day for Aussie financials

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News